Highbridge Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Highbridge Capital Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-80,000	Closed	-$4.21M	–	145
2019 Q2	$4.21M	Buy	80,000 +40,000	+100%	+$2.3M	0.28%	74
2019 Q1	$2.12M	Sell	40,000 -10,000	-20%	-$491K	0.07%	223
2018 Q4	$2.05M	Sell	50,000 -20,635	-29%	-$773K	0.06%	225
2018 Q3	$2.68M	Buy	+70,635	New	+$3.13M	0.06%	299
2016 Q4	–	Sell	-20,926	Closed	-$483K	–	1694
2016 Q3	$483K	Buy	+20,926	New	+$399K	0.01%	798

Other funds holding GBT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Highbridge Capital Management's GBT Position: Q3 2019 in Review

Highbridge Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2019, closing a stake of 80,000 shares — an estimated $4.21M sold.

Highbridge Capital Management first reported a position in GBT in Q3 2016 and held it in 5 quarters. The position peaked at $4.21M in Q2 2019. 208 funds tracked by Wall St. Rank hold GBT as of Q3 2019.

Highbridge Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
Highbridge Capital Management sold 80,000 Global Blood Therapeutics, Inc. shares in Q3 2019, an estimated $4.21M.
Highbridge Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q3 2016 and held it in 5 quarters.
Highbridge Capital Management's Global Blood Therapeutics, Inc. position peaked at $4.21M in Q2 2019.
208 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2019.

Based on Highbridge Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.